What was recalled
The U.S. Food and Drug Administration (FDA) has issued a recall for a specific batch of ophthalmic solutions manufactured by ImprimisRx NJ LLC. The product in question is the Povidone Iodine 1.25% / Proparacaine HCl 0.5% Ophthalmic Solution, packaged in 10 mL dropper bottles. It is critical to note that this medication was labeled strictly "For Office Use Only," indicating that it was not intended for direct purchase by consumers from retail shelves or pharmacies. Instead, these bottles were distributed for professional administration within medical settings, such as eye clinics, hospitals, and surgical centers.
The specific items subject to this recall are identified by the National Drug Code (NDC) 71384-732-10. The affected inventory consists of two distinct lots, each with a unique expiration date that helps identify whether they are part of the recall. The first lot is numbered 26JAN035, which carries a Best Use Date (BUD) of September 7, 2026. The second lot is identified as 26FEB015, with a Best Use Date of September 24, 2026. If you are a medical facility or healthcare provider holding inventory of this product, you must check your records against these specific lot numbers and dates to determine if your stock is impacted.
The recall was officially announced on August 24, 2026. The manufacturer, ImprimisRx NJ LLC, is located at 1705 Route 46 West, Unit 6B, in Ledgewood, New Jersey, 07852. While the product was distributed nationwide across the United States, the recall details specifically highlight distribution patterns tied to this New Jersey-based entity. Because the product was designated for office use only, it is unlikely that individual patients will have this medication in their personal possession at home. However, anyone who recently visited an ophthalmologist or eye care specialist may have been administered this solution during a procedure.
This recall is classified as a Class III by the FDA, which typically represents products that are not likely to cause adverse health reactions but still require removal from the market due to regulatory violations or quality control issues. In this case, the underlying issue is that the drug is subpotent, meaning it may not contain the correct amount of active ingredients to be effective. While the recall remedy has not been explicitly stated in the initial report, affected healthcare providers are expected to halt distribution and return the product to the manufacturer for proper disposal or replacement.
The hazard, explained
In this specific recall, the core issue is that the Povidone Iodine and Proparacaine HCl ophthalmic solution may be subpotent. While that term sounds technical, it essentially means the medicine inside the bottle does not contain the exact amount of active ingredients listed on the label. Instead of getting the full strength intended to treat an eye condition or prepare the eye for a procedure, a patient might receive a weaker dose. This is not a case of contamination or toxic impurity; rather, it is a failure of concentration. The chemical structure of the drug is intact, but the ratio of Povidone Iodine (an antiseptic) to Proparacaine HCl (a local anesthetic) is lower than what was manufactured and labeled.
To understand why this matters, we have to look at how these two ingredients work together in a medical setting. Povidone Iodine is typically used to kill bacteria, viruses, and fungi on the surface of the eye or eyelids before surgery or during treatment for infections. It relies on having a precise concentration to be effective without causing chemical burns. Proparacaine HCl is used to numb the eye so the patient does not feel pain during the examination or procedure. When these are combined in an ophthalmic solution, they must work in perfect synergy. If the solution is subpotent, the antiseptic effect may be significantly weakened. This creates a dangerous gap in protection where harmful microbes are not being adequately neutralized, potentially allowing an infection to take hold or worsen when it should have been prevented.
Furthermore, if the Proparacaine component is also subpotent, the numbing effect may be insufficient. In a clinical "Office Use Only" setting, this can lead to patient discomfort during necessary procedures, which might cause involuntary eye movements that complicate delicate surgeries or examinations. More broadly, relying on a drug that does not perform as expected undermines the entire treatment plan. If a doctor prescribes this solution to prevent post-operative infection and the drug fails to kill bacteria due to low potency, the risk of serious ocular infections increases. This is particularly concerning for patients who already have compromised immune systems or existing eye conditions.
The FDA has classified this as a Class III recall, which generally indicates that the product is unlikely to cause adverse health consequences but still fails to meet regulatory standards for purity and potency. However, in the context of eye care, where the organ is extremely sensitive and directly connected to the nervous system, "unlikely to cause harm" does not mean "safe to ignore." The mechanism of failure here is silent; you cannot see or smell that the drug is weak. It looks like normal clear liquid, but it lacks the chemical strength required for medical safety. This uncertainty is what makes subpotent drugs a significant concern in healthcare, as they provide a false sense of security while failing to deliver the protective benefits patients rely on.
Who is most at risk
To understand who is truly at risk in this recall, we first need to look at the specific nature of the product involved. This is not an over-the-counter eye drop you might keep in your bathroom cabinet for occasional redness relief. The recalled item, Povidone Iodine 1.25% / Proparacaine HCl 0.5% Ophthalmic Solution, is explicitly labeled “For Office Use Only.” This distinction is critical because it means the general public is not directly exposed to this medication in their daily lives. The primary group at risk here consists of patients who recently visited an ophthalmologist’s office, an optometrist’s clinic, or a surgical center where ImprimisRx NJ LLC products are dispensed. If you have not had a recent eye examination or procedure that involved prescription-strength drops administered by a healthcare professional, your personal risk is effectively zero.
However, for those who do use this medication, the risk profile shifts significantly due to the specific combination of ingredients and the nature of the defect. This solution contains two active drugs: Povidone-Iodine, which is an antiseptic used to prevent infection, and Proparacaine Hydrochloride, a local anesthetic that numbs the eye. The recall was issued because the product is subpotent, meaning it does not contain the full amount of active ingredient listed on the label. While this might sound like a minor quality control issue, it poses a specific, layered danger to certain patient populations.
The elderly and patients with compromised immune systems are arguably the most vulnerable. Povidone-Iodine is typically used in high-risk situations, such as before cataract surgery or other intraocular procedures, precisely to kill bacteria and prevent serious infections like endophthalmitis, which can lead to permanent vision loss. If the solution is subpotent, it may fail to adequately sterilize the eye surface. For an elderly patient whose immune response is naturally slower, or a diabetic patient with reduced healing capacity, even a minor bacterial invasion that should have been prevented can escalate into a severe, sight-threatening infection. The “subpotent” label implies that the antiseptic power was weaker than promised, leaving these vulnerable eyes exposed to pathogens they were supposed to be protected from.
Furthermore, we must consider the role of Proparacaine in this mix. As an anesthetic, it temporarily blocks pain signals. For patients who have already undergone eye surgery or treatment, masking pain can be dangerous because pain is a primary warning sign of complications like increased eye pressure or corneal damage. If a patient relies on this numbing effect to manage post-procedure discomfort, they might miss critical symptoms that would otherwise prompt them to seek immediate medical attention. This delay in recognizing trouble disproportionately affects individuals who may have difficulty communicating their symptoms clearly due to age-related cognitive changes or those who are overly trusting of the treatment’s efficacy.
In summary, the risk is not widespread across the general population but is concentrated among a specific subset of patients: those who received this exact office-use solution during a recent eye care visit. Within that group, the elderly, immunocompromised individuals, and post-surgical patients face the highest stakes because the failure of the antiseptic component could lead to infections that their bodies are less equipped to fight off naturally.
How to tell if you have the recalled item
When dealing with a medical recall, especially one involving prescription ophthalmic solutions, precision is your best friend. Vague descriptions like "eye drops" or "iodine solution" are not enough to ensure your safety. You need to verify the specific lot numbers and National Drug Codes (NDC) associated with this particular batch. The U.S. Food and Drug Administration (FDA) has identified a very specific set of identifiers for the Povidone Iodine 1.25% / Proparacaine HCl 0.5% Ophthalmic Solution recalled by ImprimisRx NJ LLC. Because these products are typically dispensed in clinical settings, they may not look like standard over-the-counter bottles you might find on a pharmacy shelf. They are specialized formulations intended for office use only.
The first thing you should check is the label on the dropper bottle. This recall affects 10 mL bottles specifically. Look closely at the National Drug Code, which serves as the unique identifier for this drug product. The affected NDC is 71384-732-10. If your bottle does not have this exact code, it is likely not part of this specific recall event. However, having the correct NDC is only half the battle; you must also verify the Lot Number to determine if your specific unit was manufactured during the affected production runs.
The recall is limited to two specific lot numbers: 26JAN035 and 26FEB015. These lot codes are typically printed clearly on the bottle label or the outer carton. If you see either of these codes, do not use the product. It is also helpful to check the Beyond Use Date (BUD) for context, although the lot number is the primary determinant. The lots associated with this recall have Beyond Use Dates of 09/07/2026 and 09/24/2026, respectively. While these dates are in the future, the chemical composition of the drug within those specific batches has been found to be subpotent, meaning it may not work as intended.
If you are a patient who received these drops during a recent eye exam or surgical procedure, contact your provider immediately. Since the distribution pattern is nationwide across the USA, but the recall notice originates from Imprimis NJ OF, LLC in Ledgewood, New Jersey, it is possible that clinics outside of New Jersey also distributed these units. Healthcare providers should check their inventory logs for NDC 71384-732-10 with the aforementioned lot numbers. If you are a medical professional reviewing your stock, physically inspecting the bottle for the lot number is critical, as visual inspection alone cannot reveal subpotency; only the printed codes can confirm if your inventory is part of this Class III recall.
What to do — step by step
If you are a healthcare provider or have recently handled the recalled Povidone Iodine 1.25% / Proparacaine HCl 0.5% Ophthalmic Solution from ImprimisRx NJ LLC, it is critical to act promptly and carefully. The FDA has classified this recall as Class III, which generally indicates that the product is unlikely to cause adverse health reactions but fails to meet manufacturing or labeling standards. In this specific case, the defect is described as a "subpotent drug," meaning the medication may not contain the full strength of active ingredients required for effective treatment. While this might sound less urgent than a recall for a toxic substance, it carries significant clinical risks that require immediate attention.
- Stop using the product immediately. The first and most important step is to cease any use of the recalled ophthalmic solution right away. Because the drug is subpotent, continuing to use it for eye procedures could lead to inadequate anesthesia or antiseptic coverage during office use. This might compromise patient safety by allowing pain or failing to prevent infection effectively. Do not administer this specific lot to any patients, and do not use any remaining stock in your practice.
- Identify the affected inventory. You must verify whether you possess any of the recalled units. Check your records for NDC 71384-732-10. Specifically, look for bottles with Lot numbers 26JAN035 (with a Best Use Date of 09/07/2026) and 26FEB015 (with a Best Use Date of 09/24/2026). These are 10 mL dropper bottles labeled "For Office Use Only." If you cannot locate the lot numbers on the physical bottle, it is safest to assume the product may be affected and set it aside for verification.
- Contact your supplier or distributor. The recall facts provided do not explicitly list a direct phone number or email address for consumers or providers to contact ImprimisRx NJ LLC directly. However, standard procedure for Class III drug recalls involving "Office Use Only" items is to reach out to the wholesaler or distributor from whom you purchased the product. They will have the necessary logistics in place to facilitate the return or credit process. Ask them specifically about the recovery plan for NDC 71384-732-10.
- Secure and isolate the product. Once identified, move the recalled bottles away from active medical supplies. Place them in a secure area to prevent accidental administration by staff who may not be aware of the recall. Properly label these items as "RECALLED - DO NOT USE" to ensure clear communication within your facility.
- Monitor for any adverse events. Although the remedy is not stated and the hazard is subpotency rather than toxicity, you should monitor any patients who may have received this product prior to the recall notice. If there were any concerns about ineffective treatment or unexpected outcomes, report these incidents to the FDA’s MedWatch program. This helps authorities understand the real-world impact of the distribution pattern across the USA.
Please remember that because the specific remedy is not detailed in the initial recall announcement, your healthcare provider network or legal counsel should be consulted for the most up-to-date instructions on returns and financial restitution. Acting quickly ensures patient safety and compliance with FDA regulations.
Your refund, repair, or replacement options
When navigating a product recall, the most pressing question for many consumers and healthcare providers is often, “What happens next regarding my money or the defective item?” In this specific instance involving ImprimisRx NJ LLC’s Povidone Iodine 1.25% / Proparacaine HCl 0.5% Ophthalmic Solution, it is crucial to approach the remedy with clarity and honesty about what information is currently available. The official recall facts released by the FDA do not explicitly state a standard consumer remedy such as a direct refund, a free replacement bottle, or a repair service. This absence of specified financial restitution terms does not mean you are without recourse, but it does mean that the process may differ from typical retail returns.
Because this product is labeled “For Office Use Only,” the primary recipients of this recall are likely healthcare facilities, ophthalmology clinics, and medical offices rather than individual patients purchasing over-the-counter items. For these professional entities, the remedy typically involves ceasing distribution and use immediately, as indicated by the Class III classification which suggests a lower risk but still requires corrective action. The standard procedure in such cases is to contact the manufacturer or distributor directly to arrange for the return of the inventory. ImprimisRx NJ LLC, located at 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852, is the responsible party. While the recall notice does not list a specific phone number or email address for this purpose, healthcare providers should reach out to their usual supply chain contacts or corporate offices of ImprimisRx to initiate a return authorization. This step ensures that the subpotent drug is removed from circulation safely and professionally.
If you are an individual who may have received this product through a medical provider, your interaction with the remedy will likely be indirect. You do not typically need to contact the manufacturer yourself for a refund in these scenarios. Instead, your healthcare provider is responsible for managing the inventory issue. They should have received notifications regarding lots 26JAN035 and 26FEB015 with their respective best-use dates of September 7, 2026, and September 24, 2026. Your provider will handle the disposal or return of the defective bottles. It is reasonable to expect that your medical office might adjust billing or provide a replacement dose at no additional cost as a matter of professional courtesy and patient care standards, even if the FDA recall document does not legally mandate it.
For now, the most important “option” available to you is verification and communication. Do not attempt to use any remaining stock from these lots. Verify the National Drug Code (NDC 71384-732-10) and lot numbers on your bottles. If you are a healthcare facility manager, document your inventory of these specific lots and prepare to contact ImprimisRx NJ LLC for disposal instructions. The lack of a stated refund policy in the public record means that any financial adjustments will be handled through direct negotiation with the supplier or as part of the clinical care relationship, rather than through a standardized online claim process. Stay patient but proactive in confirming that the product has been removed from your care environment.
What can happen if you ignore it
When a medical product is recalled for being subpotent, the danger often lies not in immediate toxicity, but in the quiet erosion of effectiveness. In this specific case involving ImprimisRx NJ LLC’s Povidone Iodine and Proparacaine HCl Ophthalmic Solution, the core issue is that the drug may not contain enough of its active ingredients to do its job properly. If you continue to use these bottles past the recall date or without replacing them with verified safe stock, you are essentially relying on a treatment that is failing you. The consequences of ignoring this are subtle but potentially significant for your eye health.
To understand why this matters, it helps to look at what these medications are designed to do. Povidone Iodine is an antiseptic commonly used in ophthalmology to prevent and treat bacterial infections, particularly around the time of surgery or after an injury. Proparacaine is a local anesthetic used to numb the eye during procedures to ensure patient comfort. When the drug is subpotent, it means the concentration of Povidone Iodine may be lower than labeled, or the Proparacaine may not provide the expected level of numbing. If you ignore the recall, you might proceed with a necessary medical procedure believing you are protected against infection when you are not. This creates a false sense of security. The risk is that bacteria could establish an infection in your eye because the antiseptic barrier was weaker than intended, leading to complications that could have been prevented.
There is also the practical issue of pain management. If the Proparacaine component is subpotent, the numbing effect may wear off too quickly or not work at all during a clinical setting. While this does not typically cause permanent harm in itself, it can lead to unnecessary discomfort for patients and potentially complicate the procedure if movement occurs due to lack of adequate anesthesia. More importantly, relying on a compromised drug means you are delaying effective care. In eye health, time is often critical. An untreated or inadequately treated corneal abrasion or pre-operative site can escalate into a more serious condition, such as keratitis or endophthalmitis, which are severe infections that threaten vision.
It is important to note that the FDA has classified this as a Class III recall. This classification indicates that while the product is unlikely to cause serious adverse health consequences or death, it still poses a significant risk because it fails to meet safety and efficacy standards. Ignoring the recall does not mean you will instantly suffer an injury, but it does mean you are accepting an uncalculated risk with your vision. The safest path is to stop using the specific lots identified—Lot #26JAN035 (BUD 09/07/2026) and Lot #26FEB015 (BUD 09/24/2026)—immediately and consult your healthcare provider for a replacement that meets all safety standards.
Staying safe: broader tips
While this specific recall highlights the importance of verifying the potency and integrity of specialized medical supplies, maintaining safety in your daily life often comes down to a few consistent, proactive habits. When it comes to pharmaceuticals and medical devices, particularly those used for sensitive applications like eye care, the line between effective treatment and potential harm can be thin. One of the most reliable ways to protect yourself is to become an active participant in the safety monitoring process rather than a passive recipient of information. The U.S. Food and Drug Administration (FDA) maintains a robust database of recalls, but waiting for news alerts is rarely enough. Instead, make it a habit to periodically check the FDA’s official recall website or subscribe to their email notifications. This ensures you are aware of issues with products you use regularly, whether they are prescription medications, over-the-counter remedies, or medical equipment, before any adverse effects occur.
For specialized items like ophthalmic solutions, storage and handling play a critical role in maintaining safety and efficacy. Even if a product has not been recalled for manufacturing defects, improper storage can degrade its chemical stability. Many eye drops and sterile solutions require specific temperature controls to remain effective. Always read the label carefully regarding storage conditions; keeping medications in humid environments like bathrooms or in direct sunlight can accelerate degradation. If you are unsure about how to store a particular product, consult your pharmacist or healthcare provider. They can provide guidance on shelf life after opening and proper disposal methods that prevent accidental exposure to children or pets.
Furthermore, communication with your healthcare team is vital when managing multiple medications or medical supplies. Keep an updated list of all the products you use, including lot numbers if available for sensitive items. This practice not only helps in recalling specific batches during a widespread safety alert but also aids your provider in identifying potential interactions or adverse reactions. By staying informed through official government channels and practicing diligent product management at home, you create a strong layer of protection that goes beyond any single recall event. Safety is not just about reacting to problems; it is about building systems that prevent them from affecting your health in the first place.